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Abstract: We would like to report an interesting case of acute sclerokeratitis following cataract surgery treated with topi-
cal use of Cyclosporine-A. A 61-year old woman with a past history of scleritis in her right eye had an uneventful phaco 
surgery in her right eye for cataract removal via a corneoscleral incision. Eight months after the initial surgery the patient 
had a sudden decrease in her visual acquity in the right eye with marked inflammatory signs in the sclera and cornea adja-
cent to the entry-site of the phaco surgery. Initially the patient was treated with systemic corticosteroids but due to serious 
side effects topical cyclosporine-A was added instead. Five months later the patient has a significant improvement in 
terms of visual acquity with marked reduction in the inflammatory signs both in sclera and corneal tissue. We think that 
topical Cyclosporine-A with its potent immunomodulating effects seems to be of benefit in those cases where systemic 
corticosteroids are contraindicated or have serious side-effects. 
INTRODUCTION 
  Surgically induced necrotizing sclerokeratitis is a rare 
destructive form of scleritis which concerns more and more 
frequently the ophthalmic community due to the rapid in-
crease of patients having cataract surgery. Cyclosporine is a 
potent immunomodulator that inhibits T-cell activation 
through inhibition of synthesis of interleukin-2, a growth 
factor for T lymphocytes. We would like to report an inter-
esting case of acute sclerokeratitis following phaco surgery 
treated with topical use of Cyclosporine-A. 
MATERIALS AND METHODS 
  A 61 year-old female patient had phaco surgery for cata-
ract removal in her right eye via a corneoscleral tunnel inci-
sion 3mm in length. The medical history of the patient was 
free of any serious disease. The ocular history included two 
episodes of anterior nodular scleritis in the right eye for 
which the work-up showed no specific cause and were both 
successfully treated with the use of systemic NSAIDS. The 
phaco surgery was uneventful and the postoperative medica-
tion included the use of dexamethazone eye drops every 2 
hours and ofloxacin eye drops every 2 hours for ten days. 
The postoperative course of the patient was asymptomatic 
until 8 months after surgery when the patient presented in the 
outpatient department of the Eye Clinic with severe pain, 
redness, lacrimation and visual loss in her right eye. The best 
corrected visual acquity in the right eye was V=1/10. Slit-
lamp examination inflammatory signs in the sclera with di-
lated episcleral and conjuctival vessels adjacent to the entry 
site of the phaco surgery. There were also inflammatory 
signs in the cornea adjacent to the entry site including 
growth of neovascular tissue between 9 and 11 clock creep-
ing through corneal stroma towards the centre of the cornea 
and early corneal thinning at this area (Fig. 1). 
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Fig. (1). Colour photo of the patient right eye. Intense inflammation 
of scleral tissue as well as neovascularization of the cornea adjacent 
to the cataract incision site. 
  There were no cells or flare in the anterior chamber and 
fundus view by an indirect ophthalmoscopy was normal. The 
intraocular pressure by applanation tonometry in the right 
eye was 17mmHg. Scrapings from the lesion were taken and 
sent to the microbiological lab for stain and culture. No or-
ganism was detected. A complete systemic work-up by an 
internist and rheumatologist failed to reveal any systemic 
disorder. A laboratory work-up (haematology, serology and 
immunology profiles) was done and the results were either 
normal or negative. Based on clinical presentation and nega-
tive systemic findings acute sclerokeratitis of non necrotiz-
ing variety was diagnosed and the patient was started ini-
tially on oral prednisolone 75 mg/day and frequent use of 
artificial tears. During the steroid therapy the patient showed 
little improvement but she developed cushinoid features and 
she refused to continue. The corticosteroids were tapered 
gradually and topical suspension of cyclosporine-A 1% pre-
pared by one of us (by admixing 10 ml of oral solution of 
Sundimnum Neoral 500mg/ml with 90ml of artificial tears 
[tears natural II –Alcon]) was added instead. The patient was 32    The Open Ophthalmology Journal, 2008, Volume 2  Doulas et al. 
given instructions to take the cyclosporine drops four times 
daily and evaluated every month. Until now the patient has 
been on cyclosporine drops for a period of five months. 
RESULTS 
  5 months after the beginning of treatment with topical 
Cyclosporine-A 1% the patient is in good condition and the 
the use of cyclosporine is tolerated very well. Slit-lamp ex-
amination of the patient right eye showed a marked reduc-
tion of inflammatory signs both in sclera and corneal tissue 
and a gradual disappearance of neovascular tissue in the cor-
nea. The cornea shows a reduction in thickness adjacent to 
the initial cataract incision and a mild amount of scarring 
into he same area (Fig. 2). 
 
Fig. (2). After treatment with topical Cyclosporine-A 1% there is 
reduction of the neovascularization in the cornea and the appear-
ance of scar tissue in upper corneal stroma. 
  The visual acquity of the patients right eye shows a mod-
erate improvement V=3/10 because of irregular astigmatism 
as a result of peripheral corneal thinning and scarring. 
DISCUSSION 
  Surgically induced necrotizing scleritis SINS, is a destruc-
tive inflammation of the sclera which can be complicated by 
keratitis, corneal ulcer, and ultimately perforation of the cor-
nea. In about 96% of cases SINS is of necrotizing variety [1]. 
Usually the scleral inflammation is developed adjacent to a 
surgical wound. Many different types of ocular surgery like 
cataract extraction, glaucoma, strabismus, retinal detachment 
surgery, pterygium excision, can induce SINS [2]. O these 
cataract surgery (phaco or ECCE) through a limbal incision 
comprises the largest subgroup. The reported latent period 
between ocular surgery and the onset of SINS is about 9 
months but it may also occur after several years in a small 
group of cases. In from 63-90% of patients SINS has been 
associated with systemic diseases like rheumatoid arthritis 
and other vasculities [3]. The pathophysiological mechanisms 
of SINS have not been established yet. Diaz-Valle et al. 
found that patients without an underlying autoimmune dis-
ease (as our patient) had the mildest form of scleral ulceration 
compared to those with a systemic disease who developed 
necrotizing scleral ulceration [4]. Neutrophile and macro-
phage infiltration around the vessel wall and the corneal 
stroma represents the first response to the surgical trauma. 
The co-existence of immune complex deposition in the cor-
nea, episcleral and scleral vessels is evidence of vasculitic 
pathology. T-cell mediated immunological responses also 
play an important role in SINS of the necrotizing variety. 
Histological evaluation of the severe cases showed the pres-
ence of T-helper cells, up-regulation of HLA-DR expression 
on the surface of scleral fibroblasts, and epithelial cells of the 
corneal ulcer and local immunoglobulin deposition (IgM, 
IgG). Addionally the fact that SINS is developed more fre-
quently following multiple surgical events suggests that it 
may be the result of a hypersensitivity reaction directed 
against an antigen revealed or altered by tissue injury. The 
increased expression of TNF-a and MMP-9 (a proinflamma-
tory cytokine and tissue degrading protease) in scleral tissue 
of patients with SINS supports this hypothesis [5]. Earlier 
studies showed a correlation between different suture materi-
als and SINS but this correlation has not been verified by 
other reports. Primary vascular closure and ischemia play a 
role but are unlikely to be important initiating events because 
in most cases SINS does not occur in the immediate postop-
erative period. Also the rapid response to immunosuppressive 
drugs implies an involvement of the immune system. The 
deregulation of all these immune mechanisms may lead to the 
development of SINS. Finally we have to consider that local 
ocular factors such as infections and conjuctival ulcers can 
also cause SINS via proteolytic enzymes and toxins and need 
to be excluded during the evaluation of the disease [6]. Man-
agement of SINS includes a preoperative evaluation to rule 
out any systemic disease. Intraoperatively, although there is 
no general consensus, clear corneal incision may be prefer-
able to corneoscleral since the disease is probably triggered 
by vascular inflammation. Post-operatively the use of high 
dose systemic corticosteroids is the first line of treatment. The 
use of NSAIDS is not effective. Cyclosporine-A is a potent 
immunomodulator that acts locally when administered at the 
ocular surface. Cyclosporine inhibits T-cell activation 
through its action as calcineurin inhibitor. This action results 
in the inhibition of the synthesis of interleukin-2, a growth 
factor for T lymphocytes Topical use of Cyclosporine-A is 
becoming popular for the prevention of allograft rejection in 
corneal transplants and for controlling immunologic or aller-
gic disorders of the ocular surface [7]. Clinical studies have 
documented that cyclosporine after topical application accu-
mulates at the ocular surface and cornea reaching concentra-
tions that are sufficient for immunomodulation. It has also 
been used as an alternative treatment to topical steroids in the 
treatment of the inflammatory response in progressive corneal 
melting. In our case a topical suspension of Cyclosporine-A 
was used since the previous steroid treatment caused severe 
cushinoid features and the patient refused to continue on ster-
oid therapy. Finally, in cases of progressive corneal and 
scleral melting we believe that despite treatment with topical 
Cyclosporine-A, a surgical management will probably be 
needed. In conclusion the Ophthalmologist should remain 
alert about the possible occurrence of SINS. The development 
of SINS after uneventful cataract surgery can be the first 
manifestation of a serious systemic disease, therefore prompt 
and early diagnosis and aggressive treatment should be initi-
ated in order to maximize a successful ocular and medical 
outcome. Given the success of topical Cyclosporine-A in 
several ocular diseases caused by T-cell dysfunction it fol-
lows that topical use of Cyclosporine-A may have value in Acute Sclerokeratitis After Cataract Surgery  The Open Ophthalmology Journal, 2008, Volume 2    33 
the treatment of SINS in the cases where systemic corticos-
teroids are contraindicated or have serious side-effects. 
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